Diagnosis, Clinical Work Up, TNM Classification, Markers

  • Jean-Luc Descotes
  • Anne-Sophie Gauchez


Prostate cancer (PCa) is the most common malignancy in developed countries, and the incidence is rapidly rising. Today, early detection is mostly induced by a large prescription of prostate-specific antigen (PSA) blood test. Although PSA remains the gold standard for diagnosis, clinical rectal examination is essential for staging prostate cancer and deciding treatment.

In this chapter, we give an overview on utilization of PSA to improve the sensibility and specificity of the test during early diagnosis. We also discuss the place of new molecular isoforms of PSA, novel blood, urine, and tissue markers useful for screening.

Finally, limits and performance of multimodal MRI as a diagnostic tool of PCa are reviewed as this imaging study is more and more useful, giving meaning to new prostate biopsy techniques and focal therapy protocols.


Prostate Cancer Prostate Biopsy Prostate Cancer Detection PCA3 Score Prostate Cancer Prevention Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aigner F, Pallwein L, Junker D et al (2010) Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25 ng/ml or greater and 4.00 ng/ml or less. J Urol 184:913–917CrossRefPubMedGoogle Scholar
  2. Aubin SMJ, Reid J et al (2010) PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride reduce trial. J Urol 184:1947–1952CrossRefPubMedGoogle Scholar
  3. Auprich M, Haese A, Walz J (2010) External validation of urinary pca3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 58:727–732CrossRefPubMedGoogle Scholar
  4. Auprich M, Bjartell A, Chun FK et al (2011) Contemporary role of PC3 in the management of prostate cancer. Eur Urol 60:1045–1054Google Scholar
  5. Barry MJ, Fowler FJ, O’Leary M et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia: the measurement committee of the American Urological Association. J Urol 148(5):1549–1557PubMedGoogle Scholar
  6. Beduschi MC, Oesterling JE (2007) Prostate-specific antigen density. Urol Clin North Am 24(2):323–332CrossRefGoogle Scholar
  7. Benson MC, Whang IS, Pantuck A et al (1992) The use of prostate specific density: a means distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147:817–821PubMedGoogle Scholar
  8. Beuzeboc P, Soulie M, Richaud P et al (2009) Gènes de fusion et cancer de la prostate. De la découverte à la valeur pronostique et aux perspectives thérapeutiques. Prog Urol 19:819–824CrossRefPubMedGoogle Scholar
  9. Canto EI, Singh H, Shariat S (2004) Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 63:905–911CrossRefPubMedGoogle Scholar
  10. Cao DL, Ye DW, Zhang HL, Wang YX et al (2010) A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate 71:700–710CrossRefPubMedGoogle Scholar
  11. Carter HB, Pearson JD, Metter EJ et al (1992) Longitudinal evaluation of prostate specific antigen levels in men with or without prostate cancer. JAMA 267(16):2215–2220CrossRefPubMedGoogle Scholar
  12. Catalona WJ, Partin AW (1998) Use of the percentage of free prostatic-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 279(19):1542–1547CrossRefPubMedGoogle Scholar
  13. Catalona WJ, Partin AW, Sanda MG et al (2011) A multicenter study of [−2]pro-prostate specific antigen ­combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185:1650–1655CrossRefPubMedGoogle Scholar
  14. Chun FK, De la Taille A (2009) Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 56:659–668CrossRefPubMedGoogle Scholar
  15. De la Taille A, Irani J et al (2011) Clinical evaluation of the pca3 assay in guiding initial biopsy decisions. J Urol 185:2119–2125CrossRefPubMedGoogle Scholar
  16. Demichelis F, Fall K, Perner S et al (2007) TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26:4596–4599CrossRefPubMedGoogle Scholar
  17. Deras IL, Aubin SMJ, Blase A et al (2008) PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179:1587–1592CrossRefPubMedGoogle Scholar
  18. Diamandis EP (2007) Point: EPCA-2 a promising new serum biomarker for prostate cancer? Clin Chem 40:1437–1439Google Scholar
  19. Dickinson L, Ahmed HU (2011) Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59:477–494CrossRefPubMedGoogle Scholar
  20. Djavan B, Kazzazi A, Dulabon L et al (2011) Diagnostic strategies for prostate cancer. Eur Urol 10:e26–e37CrossRefGoogle Scholar
  21. Ficarra V, Novara G, Zattoni F (2010) The role of the prostate cancer antigen 3 (pca3) test for the diagnosis of prostate cancer in the era of opportunistic prostate-specific antigen screening. Eur Urol 58:482–484CrossRefPubMedGoogle Scholar
  22. Gomella LG, El-Gabry EA, Strup S et al (2001) Ultrasound contrast agents for prostate imaging and biopsy. Urol Oncol 6:189–192CrossRefGoogle Scholar
  23. Guazzoni G, Nava L, Lazzeri M et al (2011) Prostate-specific antigen (psa) isoform p2psa significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total psa between 2.0 And 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 60:214–222CrossRefPubMedGoogle Scholar
  24. Haese A, De la Taille A et al (2008) Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54:1081–1088CrossRefPubMedGoogle Scholar
  25. Hamdy FC, Roupret M (2008) The PCPT trial. Prog Urol 18(3):540–543Google Scholar
  26. Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71CrossRefPubMedGoogle Scholar
  27. Jansen FH, Van Schaik RHN, Kurstjens J et al (2010) Prostate-specific antigen (psa) isoform p2psa in combination with total psa and free psa improves diagnostic accuracy in prostate cancer detection. Eur Urol 57:921–927CrossRefPubMedGoogle Scholar
  28. Jolivet-Reynaud C, Michel S, Ott C (2008) Detection of prostate-specific antigen forms and other kallikreins in prostate cancer. Med Nucl 32:24–30Google Scholar
  29. Kobus T, Hambrock T, Hulsbergen-vandeKaa CA et al (2011) In vivo assessment to prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 t with an endorectal coil. Eur Urol 60:1074–1080CrossRefPubMedGoogle Scholar
  30. Kozlowskia P, Chang SD, Meng R et al (2010) Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3 T - quantitative correlation with biopsy. Magn Reson Imaging 28:621–628CrossRefGoogle Scholar
  31. Leman ES, Cannon GW et al (2007) EPCA-2: a highly specific serum marker for prostate cancer. Urology 69(4):714–720CrossRefPubMedGoogle Scholar
  32. Mikolajczyk SD, Millar LS, Wang TJ et al (2000) “BPSA”, a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55:41–45CrossRefPubMedGoogle Scholar
  33. Mikolajczyk SD, Linton HJ et al (2004) Serum bpsa outperforms both total psa and free psa as a predictor of prostatic enlargement in men without prostate cancer. Urology 63:905–911CrossRefPubMedGoogle Scholar
  34. Morelli G, Pagni R, Mariani C (2011) Results of vardenafil mediated power Doppler ultrasound contrast enhanced ultrasound and systematic random biopsies to detect prostate cancer. J Urol 185:2126–2131CrossRefPubMedGoogle Scholar
  35. Ngo TC, Turnbull BB, Lavori PW et al (2011) The prostate cancer risk calculator from the prostate cancer prevention trial underestimates the risk of high grade cancer in contemporary referral patients. J Urol 185:483–488CrossRefPubMedGoogle Scholar
  36. Parekh DJ, Ankerst DP, Higgins BA (2006) External validation of the prostate cancer prevention trial risk calculator in a screened population. Urology 68:1152–1155CrossRefPubMedGoogle Scholar
  37. Parekh DJ, Ankerst DP et al (2007) Biomarkers for prostate cancer detection. J Urol 178:2252–2259CrossRefPubMedGoogle Scholar
  38. Partin AW, Brawer MK, Bartsch G (2003) Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 170:1787–1791CrossRefPubMedGoogle Scholar
  39. Paul B, Dhir R, Landsittel D, Hitchens MR et al (2005) Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 65:4097–4100CrossRefPubMedGoogle Scholar
  40. Payne H, Cornford P et al (2011) Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol 29:593–601CrossRefPubMedGoogle Scholar
  41. Perner S, Demichelis F, Beroukhim R et al (2006) TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66(17):8337–8341CrossRefPubMedGoogle Scholar
  42. Pondman KM, Futterer JJ, Ten Haken B et al (2008) MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol 54:517–527CrossRefPubMedGoogle Scholar
  43. Raymond C Rosen, Alan Riley, Gorm Wagner et al (1997) The International Index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49(6):823–830Google Scholar
  44. Remzi M, Haese A, Van Poppel H et al (2010) Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer? BJU Int 106(8):1138–1142CrossRefPubMedGoogle Scholar
  45. Roddam AW, Duffy MJ, Hamdy FC et al (2005) Use of prostate-specific antigen (psa) isoforms for the detection of prostate cancer in men with a psa level of 2 to 10 ng/ml: systematic review and meta-analysis. Eur Urol 48:386–399CrossRefPubMedGoogle Scholar
  46. Roobol MJ (2011) Prostate cancer biomarkers to improve risk stratification: is our knowledge of prostate cancer sufficient to spare prostate biopsies safely? Eur Urol 60:223–225CrossRefPubMedGoogle Scholar
  47. Roobol MJ, Schroder FH et al (2010) Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in pre screened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 58:475–481CrossRefPubMedGoogle Scholar
  48. Roy C, Pasquali R, Matau A et al (2010) The role of diffusion 3 –Tesla MRI in detecting prostate cancer before needle biopsy: multiparametric study of 111 patients. J Radiol 91:1121–1128CrossRefPubMedGoogle Scholar
  49. Salami SS, Schmidt F, Laxman B et al (2011) Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol OncolGoogle Scholar
  50. Salomon G, Kollerman J, Thederan I et al (2008) Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. Eur Urol 54:1354–1362CrossRefPubMedGoogle Scholar
  51. Scherra MK, Seitz M, Müller-Lissea UG (2010) MR-perfusion (MRP) and diffusion-weighted imaging (DWI) in prostate cancer: quantitative and model-based gadobenate dimeglumine MRP parameters in detection of prostate cancer. Eur J Radiol 76:359–366CrossRefGoogle Scholar
  52. Schostak M, Schwall GP, Poznanovic S et al (2009) Annexin A3 in urine: a highly specific non-invasive marker for prostate cancer early detection. J Urol 191:343–353CrossRefGoogle Scholar
  53. Schroder F, Carter HB et al (2008) Early detection of prostate cancer in 2007 part 1: PSA and PSA kinetics. Eur Urol 53:468–477CrossRefPubMedGoogle Scholar
  54. Sciarra A, Barentsz J, Bjartell A et al (2011) Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 59:962–977CrossRefPubMedGoogle Scholar
  55. Sokoll LJ, Wang Y et al (2008) [−2] proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 180:539–543CrossRefPubMedGoogle Scholar
  56. Sreekumar A, Poisson LM, Rajendiranl TM et al (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457:910–915CrossRefPubMedGoogle Scholar
  57. Steuber T, O’Brien MF, Lilja H (2008) Serum markers for prostate cancer: a rational approach to the literature. Eur Urol 54:31–40CrossRefPubMedGoogle Scholar
  58. Teillac P, Abrahamsson PA (2006) The prostate cancer prevention trial and its implications for clinical practice: a European consensus. Eur Urol Suppl 5:640–646CrossRefGoogle Scholar
  59. Tomlins SA, Aubin SMJ, Siddiqui J et al (2011) Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 3(94):1–12CrossRefGoogle Scholar
  60. Vlaeminck-Guillem V, Devonec M, Colombel M et al (2011) Urinary PCA3 score predicts prostate cancer multifocality. J Urol 185:1234–1239CrossRefPubMedGoogle Scholar
  61. Walz A, Marcyb M, Maubonc T (2011) Real time elastography in the diagnosis of prostate cancer: comparison of preoperative imaging and histology after radical prostatectomy. Prog Urol 21:925–931CrossRefPubMedGoogle Scholar
  62. Whitman EJ, Groskopf J et al (2008) PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 180:1975–1979CrossRefPubMedGoogle Scholar
  63. Wink M, Frauscher F, Cosgrove D et al (2008) Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination project. Eur Urol 54:982–993CrossRefPubMedGoogle Scholar
  64. Zhigang Z, Guohua Z, Wen Z (2010) Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection, of the prostate for benign prostatic hyperplasia. Prostate 70:1788–1798Google Scholar
  65. Zhigang Z, Wenjing M, Guohua Z et al (2011) Serum early prostate cancer antigen (EPCA) level and its association with decrease progression in prostate cancer in a Chinese population. PLoS One 6(5):e19284CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Urology and Renal TransplantCHU GRENOBLEGrenobleFrance
  2. 2.Department of BiologyCHU GRENOBLEGrenobleFrance

Personalised recommendations